Biography

Dr. Steven Gray earned his Ph.D. in molecular biology from Vanderbilt University in 2006, after receiving a B.S. degree with honors from Auburn University. He performed a postdoctoral fellowship focusing on gene therapy in the laboratory of Jude Samulski at UNC Chapel Hill. He is currently an Associate Professor in the Department of Pediatrics at the University of Texas Southwestern Medical Center.

Dr. Gray’s core expertise is in AAV gene therapy vector engineering, followed by optimizing approaches to deliver a gene to the nervous system. His major focus is in AAV vector development to develop vectors tailored to serve specific clinical and research applications involving the nervous system. These include the development of novel AAV capsids amenable to widespread CNS gene transfer. As AAV-based platform gene transfer technologies have been developed to achieve global, efficient, and in some cases cell-type specific CNS gene delivery, his research focus has also included preclinical studies to apply these reagents toward the development of treatments for neurological diseases. Currently these include preclinical studies for Rett Syndrome, Giant Axonal Neuropathy (GAN), Tay-Sachs, Krabbe, AGU, and Batten Disease, and have expanded into human clinical studies to test a gene therapy approach for GAN.

Dr. Gray has published over 50 peer-reviewed papers in journals such as New England Journal of Medicine, Molecular Therapy, Nature Biotechnology, Gene Therapy, and The Proceedings of the National Academy of Sciences. He also has 3 pending patents. His research is funded by the National Institute for Neurological Disorders and Stroke, as well as numerous large and small research foundations. Dr. Gray was recently recognized with the 2016 Healthcare Hero award by the Triangle Business Journal, and his work on GAN was featured in a story by the CBS National Evening News in 2015.

Research Interest

  • Adeno-Associated Virus (AAV) vector engineering
  • Developing AAV vector-based treatments (gene therapy) for nervous system diseases
  • Facilitating bench-to-bedside translation of gene therapy into Phase I clinical trials
  • Improving AAV vector manufacturing processes
  • Understanding and overcoming immune responses associated with viral vector-based gene therapy approaches

Publications

Featured Publications LegendFeatured Publications

Recent endeavors in MECP2 gene transfer for gene therapy of Rett syndrome.
Sinnett SE, Gray SJ Discov Med 2017 Oct 24 132 153-159
Temporal associations between national outbreaks of meningococcal serogroup W and C disease in the Netherlands and England: an observational cohort study.
Knol MJ, Hahné SJM, Lucidarme J, Campbell H, de Melker HE, Gray SJ, Borrow R, Ladhani SN, Ramsay ME, van der Ende A Lancet Public Health 2017 Oct 2 10 e473-e482
Frequent capsule switching in 'ultra-virulent' meningococci - Are we ready for a serogroup B ST-11 complex outbreak?
Lucidarme J, Lekshmi A, Parikh SR, Bray JE, Hill DM, Bratcher HB, Gray SJ, Carr AD, Jolley KA, Findlow J, Campbell H, Ladhani SN, Ramsay ME, Maiden MCJ, Borrow R J. Infect. 2017 Aug 75 2 95-103
Meningococcal serogroup B strain coverage of the multicomponent 4CMenB vaccine with corresponding regional distribution and clinical characteristics in England, Wales, and Northern Ireland, 2007-08 and 2014-15: a qualitative and quantitative assessment.
Parikh SR, Newbold L, Slater S, Stella M, Moschioni M, Lucidarme J, De Paola R, Giuliani M, Serino L, Gray SJ, Clark SA, Findlow J, Pizza M, Ramsay ME, Ladhani SN, Borrow R Lancet Infect Dis 2017 Jul 17 7 754-762
Novel oligodendroglial alpha synuclein viral vector models of multiple system atrophy: studies in rodents and nonhuman primates.
Mandel RJ, Marmion DJ, Kirik D, Chu Y, Heindel C, McCown T, Gray SJ, Kordower JH Acta Neuropathol Commun 2017 Jun 5 1 47
Development of a Novel AAV Gene Therapy Cassette with Improved Safety Features and Efficacy in a Mouse Model of Rett Syndrome.
Gadalla KKE, Vudhironarit T, Hector RD, Sinnett S, Bahey NG, Bailey MES, Gray SJ, Cobb SR Mol Ther Methods Clin Dev 2017 Jun 5 180-190
Improved MECP2 Gene Therapy Extends the Survival of MeCP2-Null Mice without Apparent Toxicity after Intracisternal Delivery.
Sinnett SE, Hector RD, Gadalla KKE, Heindel C, Chen D, Zaric V, Bailey MES, Cobb SR, Gray SJ Mol Ther Methods Clin Dev 2017 Jun 5 106-115
Functional Analysis of the Ser149/Thr149 Variants of Human Aspartylglucosaminidase and Optimization of the Coding Sequence for Protein Production.
Banning A, König JF, Gray SJ, Tikkanen R Int J Mol Sci 2017 Mar 18 4
N-acetylaspartate supports the energetic demands of developmental myelination via oligodendroglial aspartoacylase.
Francis JS, Wojtas I, Markov V, Gray SJ, McCown TJ, Samulski RJ, Bilaniuk LT, Wang DJ, De Vivo DC, Janson CG, Leone P Neurobiol. Dis. 2016 Dec 96 323-334
Identification of Small Molecule Compounds for Pharmacological Chaperone Therapy of Aspartylglucosaminuria.
Banning A, Gülec C, Rouvinen J, Gray SJ, Tikkanen R Sci Rep 2016 Nov 6 37583

Books

Featured Books Legend Featured Books

Honors & Awards

  • Triangle Business Journal’s 2016 Health Care Hero Award
    (2016)

Professional Associations/Affiliations

  • Cure SPG47 Scientific Advisory Board (2016)
  • Foundation to Fight H-ABC Scientific Advisory Board (2016)
  • Galyatech, LLC Scientific Advisory Board (2016)
  • Hunter’s Hope Foundation Scientific Advisory Board (2015)
  • Hereditary Neuropathy Foundation Scientific Advisory Board (2014)
  • International Rett Syndrome Foundation Scientific Review Board (2011)